Protection against mucosal SHIV challenge by peptide and helper-dependent adenovirus vaccines

Eric A Weaver, Pramod N. Nehete, Bharti P. Nehete, Stephanie J. Buchl, Donna Palmer, David C. Montefiori, Philip Ng, K. Jagannadha Sastry, Michael A. Barry

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Groups of rhesus macaques that had previously been immunized with HIV-1 envelope (env) peptides and first generation adenovirus serotype 5 (FG-Ad5) vaccines expressing the same peptides were immunized intramuscularly three times with helperdependent adenovirus (HD-Ad) vaccines expressing only the HIV-1 envelope from JRFL. No gag, pol, or other SHIV genes were used for vaccination. One group of the FG-Ad5- immune animals was immunized three times with HD-Ad5 expressing env. One group was immunized by serotype-switching with HD-Ad6, HD-Ad1, and HD-Ad2 expressing env. Previous work demonstrated that serum antibody levels against env were significantly higher in the serotype-switched group than in the HD-Ad5 group. In this study, neutralizing antibody and T cell responses were compared between the groups before and after rectal challenge with CCR5-tropic SHIV-SF162P3. When serum samples were assayed for neutralizing antibodies, only weak activity was observed. T cell responses against env epitopes were higher in the serotype-switched group. When these animals were challenged rectally with SHIV-SF162P3, both the Ad5 and serotype-switch groups significantly reduced peak viral loads 2 to 10-fold 2 weeks after infection. Peak viral loads were significantly lower for the serotype-switched group as compared to the HD-Ad5-immunized group. Viral loads declined over 18 weeks after infection with some animals viremia reducing nearly 4 logs from the peak. These data demonstrate significant mucosal vaccine effects after immunization with only env antigens. These data also demonstrate HD-Ad vectors are a robust platform for vaccination.

Original languageEnglish (US)
Pages (from-to)920-938
Number of pages19
JournalViruses
Volume1
Issue number3
DOIs
StatePublished - Nov 10 2009

Fingerprint

Adenovirus Vaccines
Peptides
Viral Load
Adenoviridae
Neutralizing Antibodies
HIV-1
Vaccination
Vaccines
T-Lymphocytes
Viremia
Infection
Serogroup
Macaca mulatta
Serum
Epitopes
Immunization
Antigens
Antibodies

Keywords

  • Adenovirus
  • HIV-1
  • Helper-dependent vector
  • Mucosal challenge
  • SHIV
  • Serotype-switching

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

Weaver, E. A., Nehete, P. N., Nehete, B. P., Buchl, S. J., Palmer, D., Montefiori, D. C., ... Barry, M. A. (2009). Protection against mucosal SHIV challenge by peptide and helper-dependent adenovirus vaccines. Viruses, 1(3), 920-938. https://doi.org/10.3390/v1030920

Protection against mucosal SHIV challenge by peptide and helper-dependent adenovirus vaccines. / Weaver, Eric A; Nehete, Pramod N.; Nehete, Bharti P.; Buchl, Stephanie J.; Palmer, Donna; Montefiori, David C.; Ng, Philip; Jagannadha Sastry, K.; Barry, Michael A.

In: Viruses, Vol. 1, No. 3, 10.11.2009, p. 920-938.

Research output: Contribution to journalArticle

Weaver, EA, Nehete, PN, Nehete, BP, Buchl, SJ, Palmer, D, Montefiori, DC, Ng, P, Jagannadha Sastry, K & Barry, MA 2009, 'Protection against mucosal SHIV challenge by peptide and helper-dependent adenovirus vaccines', Viruses, vol. 1, no. 3, pp. 920-938. https://doi.org/10.3390/v1030920
Weaver EA, Nehete PN, Nehete BP, Buchl SJ, Palmer D, Montefiori DC et al. Protection against mucosal SHIV challenge by peptide and helper-dependent adenovirus vaccines. Viruses. 2009 Nov 10;1(3):920-938. https://doi.org/10.3390/v1030920
Weaver, Eric A ; Nehete, Pramod N. ; Nehete, Bharti P. ; Buchl, Stephanie J. ; Palmer, Donna ; Montefiori, David C. ; Ng, Philip ; Jagannadha Sastry, K. ; Barry, Michael A. / Protection against mucosal SHIV challenge by peptide and helper-dependent adenovirus vaccines. In: Viruses. 2009 ; Vol. 1, No. 3. pp. 920-938.
@article{90fbb5399e614c0e9d4688c462072b39,
title = "Protection against mucosal SHIV challenge by peptide and helper-dependent adenovirus vaccines",
abstract = "Groups of rhesus macaques that had previously been immunized with HIV-1 envelope (env) peptides and first generation adenovirus serotype 5 (FG-Ad5) vaccines expressing the same peptides were immunized intramuscularly three times with helperdependent adenovirus (HD-Ad) vaccines expressing only the HIV-1 envelope from JRFL. No gag, pol, or other SHIV genes were used for vaccination. One group of the FG-Ad5- immune animals was immunized three times with HD-Ad5 expressing env. One group was immunized by serotype-switching with HD-Ad6, HD-Ad1, and HD-Ad2 expressing env. Previous work demonstrated that serum antibody levels against env were significantly higher in the serotype-switched group than in the HD-Ad5 group. In this study, neutralizing antibody and T cell responses were compared between the groups before and after rectal challenge with CCR5-tropic SHIV-SF162P3. When serum samples were assayed for neutralizing antibodies, only weak activity was observed. T cell responses against env epitopes were higher in the serotype-switched group. When these animals were challenged rectally with SHIV-SF162P3, both the Ad5 and serotype-switch groups significantly reduced peak viral loads 2 to 10-fold 2 weeks after infection. Peak viral loads were significantly lower for the serotype-switched group as compared to the HD-Ad5-immunized group. Viral loads declined over 18 weeks after infection with some animals viremia reducing nearly 4 logs from the peak. These data demonstrate significant mucosal vaccine effects after immunization with only env antigens. These data also demonstrate HD-Ad vectors are a robust platform for vaccination.",
keywords = "Adenovirus, HIV-1, Helper-dependent vector, Mucosal challenge, SHIV, Serotype-switching",
author = "Weaver, {Eric A} and Nehete, {Pramod N.} and Nehete, {Bharti P.} and Buchl, {Stephanie J.} and Donna Palmer and Montefiori, {David C.} and Philip Ng and {Jagannadha Sastry}, K. and Barry, {Michael A.}",
year = "2009",
month = "11",
day = "10",
doi = "10.3390/v1030920",
language = "English (US)",
volume = "1",
pages = "920--938",
journal = "Viruses",
issn = "1999-4915",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

TY - JOUR

T1 - Protection against mucosal SHIV challenge by peptide and helper-dependent adenovirus vaccines

AU - Weaver, Eric A

AU - Nehete, Pramod N.

AU - Nehete, Bharti P.

AU - Buchl, Stephanie J.

AU - Palmer, Donna

AU - Montefiori, David C.

AU - Ng, Philip

AU - Jagannadha Sastry, K.

AU - Barry, Michael A.

PY - 2009/11/10

Y1 - 2009/11/10

N2 - Groups of rhesus macaques that had previously been immunized with HIV-1 envelope (env) peptides and first generation adenovirus serotype 5 (FG-Ad5) vaccines expressing the same peptides were immunized intramuscularly three times with helperdependent adenovirus (HD-Ad) vaccines expressing only the HIV-1 envelope from JRFL. No gag, pol, or other SHIV genes were used for vaccination. One group of the FG-Ad5- immune animals was immunized three times with HD-Ad5 expressing env. One group was immunized by serotype-switching with HD-Ad6, HD-Ad1, and HD-Ad2 expressing env. Previous work demonstrated that serum antibody levels against env were significantly higher in the serotype-switched group than in the HD-Ad5 group. In this study, neutralizing antibody and T cell responses were compared between the groups before and after rectal challenge with CCR5-tropic SHIV-SF162P3. When serum samples were assayed for neutralizing antibodies, only weak activity was observed. T cell responses against env epitopes were higher in the serotype-switched group. When these animals were challenged rectally with SHIV-SF162P3, both the Ad5 and serotype-switch groups significantly reduced peak viral loads 2 to 10-fold 2 weeks after infection. Peak viral loads were significantly lower for the serotype-switched group as compared to the HD-Ad5-immunized group. Viral loads declined over 18 weeks after infection with some animals viremia reducing nearly 4 logs from the peak. These data demonstrate significant mucosal vaccine effects after immunization with only env antigens. These data also demonstrate HD-Ad vectors are a robust platform for vaccination.

AB - Groups of rhesus macaques that had previously been immunized with HIV-1 envelope (env) peptides and first generation adenovirus serotype 5 (FG-Ad5) vaccines expressing the same peptides were immunized intramuscularly three times with helperdependent adenovirus (HD-Ad) vaccines expressing only the HIV-1 envelope from JRFL. No gag, pol, or other SHIV genes were used for vaccination. One group of the FG-Ad5- immune animals was immunized three times with HD-Ad5 expressing env. One group was immunized by serotype-switching with HD-Ad6, HD-Ad1, and HD-Ad2 expressing env. Previous work demonstrated that serum antibody levels against env were significantly higher in the serotype-switched group than in the HD-Ad5 group. In this study, neutralizing antibody and T cell responses were compared between the groups before and after rectal challenge with CCR5-tropic SHIV-SF162P3. When serum samples were assayed for neutralizing antibodies, only weak activity was observed. T cell responses against env epitopes were higher in the serotype-switched group. When these animals were challenged rectally with SHIV-SF162P3, both the Ad5 and serotype-switch groups significantly reduced peak viral loads 2 to 10-fold 2 weeks after infection. Peak viral loads were significantly lower for the serotype-switched group as compared to the HD-Ad5-immunized group. Viral loads declined over 18 weeks after infection with some animals viremia reducing nearly 4 logs from the peak. These data demonstrate significant mucosal vaccine effects after immunization with only env antigens. These data also demonstrate HD-Ad vectors are a robust platform for vaccination.

KW - Adenovirus

KW - HIV-1

KW - Helper-dependent vector

KW - Mucosal challenge

KW - SHIV

KW - Serotype-switching

UR - http://www.scopus.com/inward/record.url?scp=79959267169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959267169&partnerID=8YFLogxK

U2 - 10.3390/v1030920

DO - 10.3390/v1030920

M3 - Article

VL - 1

SP - 920

EP - 938

JO - Viruses

JF - Viruses

SN - 1999-4915

IS - 3

ER -